Hematopoietic cell transplantation - specific comorbidity index (HCT-CI)

About

The Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplantation population and to enable risk assessment before allogeneic transplant. Data were collected retrospectively from 1055 patients undergoing nonablative (n=294) and ablative (n=761) conditioning prior to stem cell transplantation. Median age of the group was 45 and myeloid malignancies constituted the majority of diagnoses (66%). The investigators identified relevant comorbidities and derived a scoring system that predicted for 2-year non-relapse mortality post transplantation, after adjusting for age, disease risk, and conditioning regimen. The HCT-CI is able to classify patients into three risk groups: low risk (non-relapse mortality 14% at 2-years), intermediate risk (non-relapse mortality 21% at 2-years) and high risk (non-relapse mortality 41% at 2-years). The authors caution that other major pretransplant factors, including age and disease stage, should be considered when determining risk for allogeneic transplant.

References

Mohamed L Sorror, Michael B Maris, Rainer Storb, Frederic Baron, Brenda M Sandmaier, David G Maloney, Barry Storer

Blood 2005 October 15, 106 (8): 2912-9
Default Units

1. Arrhythmia?

More Information

Arrhythmia Defined as: Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias

0/15 completed

About

The Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplantation population and to enable risk assessment before allogeneic transplant. Data were collected retrospectively from 1055 patients undergoing nonablative (n=294) and ablative (n=761) conditioning prior to stem cell transplantation. Median age of the group was 45 and myeloid malignancies constituted the majority of diagnoses (66%). The investigators identified relevant comorbidities and derived a scoring system that predicted for 2-year non-relapse mortality post transplantation, after adjusting for age, disease risk, and conditioning regimen. The HCT-CI is able to classify patients into three risk groups: low risk (non-relapse mortality 14% at 2-years), intermediate risk (non-relapse mortality 21% at 2-years) and high risk (non-relapse mortality 41% at 2-years). The authors caution that other major pretransplant factors, including age and disease stage, should be considered when determining risk for allogeneic transplant.

References

Mohamed L Sorror, Michael B Maris, Rainer Storb, Frederic Baron, Brenda M Sandmaier, David G Maloney, Barry Storer

Blood 2005 October 15, 106 (8): 2912-9
Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.